Study of lipid profiles high and normal body mass index in polycystic ovary syndrome women in Aljouf, Saudi Arabia
Keywords:High BMI, Lipid profiles, Normal BMI, PCOS
Background: For women of reproductive age, polycystic ovary syndrome (PCOS) is the most prevalent endocrinological condition. Hyperandrogenism, persistent ovulatory dysfunction, obesity, and insulin resistance have all been associated with PCOS. However, recently PCOS is detected in high-body weight and normal-body-weight women. No information was available to evaluate specific lipid profiles. The goal of this study is to analyze the lipid profiles of women with polycystic ovarian syndrome who have high or normal body weight.
Methods: This polycystic ovarian syndrome (PCOS) retrospective study was carried out between January 2021 and January 2022 at Sakaka’s Maternity and Children Hospital (MCH), Aljouf, Saudi Arabia. A total of 68 PCOS women were included in the study; we divided them into high (n=34) and normal body weight (n=34) according to the calculation of BMI. We obtain the test results of lipid profiles and demographic data from hospital record files.
Results: We noticed changes but no significance in our research of lipid profiles in high and normal PCOS participants. The CHOL, TG, HDL, and LDL, 159.30±4.193, 97.89±7.140, 60.91±9.564, and 99.47±9.22 shown in the high BMI PCOS women respectively. While, 129.28±3.702, 83.69±4.49, 46.84±1.68 and86.53±4.36 were detected in normal BMI PCOS women respectively. There were none that were statistically significant, with the exception of cholesterol p=0.001.
Conclusions: Our results show that POCS women with normal body weight and PCOS women with high BMI have different changes in their lipid profiles, but no significance has been found other than higher cholesterol levels. Therefore, losing weight can stop lipid profiles from altering, which may reduce difficulties in the future.
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31.
Diamanti-Kandarakis E, Christakou C, Marinakis E. Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des. 2012;18(3): 270-82.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-92.
Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1-29.
Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, et al. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism. 1995;44(4):525-31.
Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab. 2003;88(10):4682-8.
Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001 Jun 1;86(6):2453-5.
Xiong YL, Liang XY, Yang X, Li Y, Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;159:148-50.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45.
Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, Aliasgharzadeh A, Aliashrafi S, Rezayi N, et al. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome. J Health Popul Nutr. 2015;33(1):157.
Al-Alak MMA, Omran ZS, Abdul-Qahar ZH. Effect of thyroid peroxidase antibodies (TPO) on endometrium thickness (ET)- Ova size in infertile women in Kerbala a descriptive study. Kerbala J Pharm Sci. 2016;11.
Senaldi L, Gopi RP, Milla S, Shah B. Is ultrasound useful in the diagnosis of adolescents with polycystic ovary syndrome? J Pediatr Endocrinol Metab. 2015;28(5-6):605-12.
Suha SA, Islam MN. An extended machine learning technique for polycystic ovary syndrome detection using ovary ultrasound image. Scient Rep. 2022;12:17123.
Al-Faris NN, Al-Tu’ma FJ, Al-Safi WG. Assessments of C-reactive protein and its correlation with total antioxidant capacity in woman with poly cystic ovary syndrome. Iraqi Nat J Chem. 2017;17(1).
Güdücü N, Görmüş U, Kayan ÖB, Kavak ZN, Dünder İ. The relationship between affective disorders and hormonal and metabolic parameters in women with polycystic ovary syndrome. J Clin Exp Investig. 2013;4(1).
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108-20.